10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say

For the quarter ended June 2025, 10x Genomics (TXG) reported revenue of $172.91 million, up 12.9% over the same period last year. EPS came in at $0.28, compared to -$0.32 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $139.44 million, representing a surprise of +24%. The company delivered an EPS surprise of +180%, with the consensus EPS estimate being -$0.35.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how 10x Genomics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenues- Consumables: $122.19 million compared to the $117.21 million average estimate based on two analysts. The reported number represents a change of -1% year over year.Revenues- Instruments: $14.5 million compared to the $14.9 million average estimate based on two analysts. The reported number represents a change of -39.2% year over year.Revenues- Instruments- Chromium: $5.73 million versus $5.6 million estimated by two analysts on average.Revenues- Services: $8.48 million versus $7.36 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +43.9% change.Revenues- Consumables- Chromium: $85.79 million versus $84.35 million estimated by two analysts on average.Revenues- Consumables- Spatial: $36.4 million compared to the $32.86 million average estimate based on two analysts.Revenues- Instruments- Spatial: $8.77 million versus the two-analyst average estimate of $9.3 million.View all Key Company Metrics for 10x Genomics here>>>Shares of 10x Genomics have returned +4.6% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Beyond Nvidia: AI's Second Wave Is HereThe AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.See "2nd Wave" AI stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report 10x Genomics (TXG): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks